Real-world utilization and outcomes of dacomitinib as first-line therapy in Asian patients with advanced EGFR mutation-positive NSCLC: An interim analysis of the ARIA study

被引：0
|
作者：
Wu, L. [1 ,2 ]
Li, J. [3 ]
Xu, C. [4 ,5 ]
Biswas, B. [6 ]
Tang, K. [7 ]
Wang, H. [8 ,9 ]
Liu, Z. [10 ]
Batra, U. [11 ]
Ho, G. F. [12 ]
Low, S. H. J. [13 ]
Lu, Y. [14 ]
Zhao, M. [15 ]
Tho, L. M. [16 ]
Zhao, J. [17 ]
He, S. [18 ]
Huang, J. [19 ]
Tang, X. [20 ]
Wong, C. H. [21 ]
Wu, Y-L. [4 ,5 ]
机构：
[1] Cent South Univ, Dept Med Oncol, Hunan Canc Hosp, Changsha, Peoples R China
[2] Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, China Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
[4] Guangdong Prov Peoples Hosp, Lung Canc Inst, Guangzhou, Peoples R China
[5] Guangdong Acad Med Sci, Guangzhou, Peoples R China
[6] Tata Med Ctr, Dept Med Oncol, Kolkata, India
[7] Sun Yat Sen Univ, Resp & Crit Care Med Dept, Affiliated Hosp 1, Guangzhou, Peoples R China
[8] Zhengzhou Univ, Dept Med Oncol, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[9] Henan Canc Hosp, Zhengzhou, Peoples R China
[10] First Hosp Jilin Univ, Dept Oncol Ctr, Changchun, Peoples R China
[11] Rajiv Gandhi Canc Inst & Res Ctr, Dept Med Oncol, New Delhi, India
[12] Univ Malaya, Dept Clin Oncol, Med Ctr, Kuala Lumpur, Malaysia
[13] Pantai Hosp, Oncol & Radiotherapy, Kuala Lumpur, Malaysia
[14] Sichuan Univ, West China Sch Clin Med, West China Hosp, Oncol, Chengdu, Peoples R China
[15] China Med Univ, Dept Oncol, Hosp 1, Shenyang, Peoples R China
[16] Beacon Hosp, Dept Clin Oncol, Petaling Jaya, Malaysia
[17] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Thorac Oncol, Minist Educ, Beijing, Peoples R China
[18] Pfizer Inc, Clin Dev, Shanghai, Peoples R China
[19] Pfizer China Res & Dev Co Ltd, Clin Data Qual Dev China, Shanghai, Peoples R China
[20] Pfizer Inc, Pfizer GB & DM, CHN Stat, Shanghai, Peoples R China
[21] Pfizer Pte Ltd, Med Affairs, Singapore, Singapore
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2370
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1337P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
    Lu, Shun
    Shih, Jin-Yuan
    Jang, Tae-Won
    Liam, Chong-Kin
    Yu, Yongfeng
    ADVANCES IN THERAPY, 2021, 38 (05) : 2038 - 2053
  • [2] Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
    Shun Lu
    Jin-Yuan Shih
    Tae-Won Jang
    Chong-Kin Liam
    Yongfeng Yu
    Advances in Therapy, 2021, 38 : 2038 - 2053
  • [3] Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
    Liang, Sheng-Kai
    Hsieh, Min-Shu
    Lee, Meng-Rui
    Keng, Li-Ta
    Ko, Jen-Chung
    Shih, Jin-Yuan
    ONCOTARGET, 2017, 8 (52) : 90430 - 90443
  • [4] Real-world outcomes of first-line osimertinib for EGFR mutated advanced NSCLC patients in China: Interim analysis of the FLOURISH study
    Zhou, J.
    Zhou, J.
    Zheng, J.
    Wang, K.
    Tang, K.
    Lu, D.
    Cui, J.
    Zhu, D.
    Wang, Y.
    Zhao, Y.
    Xing, L.
    Ding, L.
    Shi, X.
    Shen, L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1065 - S1065
  • [5] Real-world dose adjustment study of first-line afatinib in pts with EGFR mutation-positive (EGFRm plus ) advanced NSCLC.
    Halmos, Balazs
    Tan, Eng-Huat
    Lee, Min Ki
    Foucher, Pascal
    Hsia, Te-Chun
    Hochmair, Maximilian J.
    Griesinger, Frank
    Hida, Toyoaki
    Kim, Edward S.
    Melosky, Barbara L.
    Maerten, Angela
    Costa, Enric Carcereny
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Real-world utilization of EGFR TKI therapies and treatment outcomes in patients with advanced EGFR-sensitizing mutation-positive NSCLC.
    Riely, Gregory J.
    Lovly, Christine Marie
    Messina, Carlo G. M.
    Bienert, Stefanie
    Alexander, Kimberly
    Pao, William
    Baxi, Shrujal
    Doebele, Robert Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Furmonertinib as First-Line Therapy for Chinese Patients with EGFR Mutation-positive NSCLC: A RealWorld Study
    Yan, N. N.
    Guo, S.
    Huang, S.
    Zhang, H.
    Li, X.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S622 - S622
  • [8] The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study)
    Watanabe, Kageaki
    Hosomi, Yukio
    Naoki, Katsuhiko
    Nakahara, Yoshiro
    Tsukita, Yoko
    Matsumoto, Hirotaka
    Yoh, Kiyotaka
    Fujisaka, Yasuhito
    Takahashi, Satoshi
    Takata, Saori
    Usui, Kazuhiro
    Kishi, Kazuma
    Naka, Go
    Tamano, Shu
    Uemura, Kohei
    Kunitoh, Hideo
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (11):
  • [9] Afatinib followed by osimertinib in patients with EGFR mutation-positive advanced NSCLC: A real-world study (GioTag)
    Hochmair, M. J.
    Morabito, A.
    Hao, D.
    Yang, C-T.
    Soo, R. A.
    Yang, J. C-H.
    Gucalp, R.
    Halmos, B.
    Wang, L.
    Golembesky, A.
    Maerten, A.
    Cufer, T.
    ANNALS OF ONCOLOGY, 2018, 29
  • [10] Afatinib Followed by Osimertinib in Real-World Patients with EGFR Mutation-Positive Advanced NSCLC: The Giotag Study
    Hochmair, M. J.
    Morabito, A.
    Hao, D.
    Yang, C.
    Soo, R.
    Yang, J. C.
    Gucalp, R.
    Halmos, B.
    Golembesky, A.
    Maerten, A.
    Cufer, T.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1045 - S1045
12345